Related Experiment Videos
The combined suppression/stimulation therapy in IVF-ET programmes: expectations and facts
V Insler1, G Potashnik, E Lunenfeld
1Division of Obstetrics and Gynaecology, Soroka Medical Centre, Beer-Sheba, Israel.
Human Reproduction (Oxford, England)
|November 1, 1989
Summary
Combined pituitary suppression and ovarian stimulation therapy in IVF-ET improves outcomes by preventing premature LH surges and synchronizing responses. This leads to more eggs and higher pregnancy rates in fertility treatments.
Area of Science:
- Reproductive Endocrinology
- In Vitro Fertilization
Background:
- In Vitro Fertilization-Embryo Transfer (IVF-ET) programs aim to optimize pregnancy rates.
- Premature luteinizing hormone (LH) secretion can negatively impact IVF-ET success.
Purpose of the Study:
- To evaluate the benefits of combined pituitary suppression and ovarian stimulation therapy in IVF-ET.
- To explore methods for improving ovarian response synchronization and pregnancy rates.
Main Methods:
- Utilizing gonadotropin-releasing hormone (GnRH) analogues for pituitary suppression.
- Administering gonadotropins for ovarian stimulation.
- Comparing outcomes with and without combined therapy.
Main Results:
- Combined therapy effectively prevents untimely LH secretion and synchronizes ovarian response.
- This approach can lead to increased oocyte retrieval and embryo replacement.
- Higher pregnancy rates are associated with this combined treatment protocol.
Conclusions:
- Combined GnRH analogue/gonadotropin therapy is crucial for avoiding premature luteinization and enhancing IVF-ET success.
- Further research into novel treatment schemes, including GnRH antagonists, is needed for optimized ovarian response.
- Understanding the direct effects of GnRH analogues on ovarian function will refine combined therapy application.